[Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry].
作者信息
Hansen Lars, Andersen Dorrit
机构信息
Novo Nordisk A/S, Måløv.
出版信息
Ugeskr Laeger. 2005 May 16;167(20):2160-4.
PMID:15987073
Abstract
摘要
相似文献
1
[Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry].
Ugeskr Laeger. 2005 May 16;167(20):2160-4.
2
[Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency].
Ugeskr Laeger. 2005 May 16;167(20):2146-50.
3
Pharmacogenomics: will the regulators approve?
Nat Biotechnol. 1998 Mar;16(3):243-6. doi: 10.1038/nbt0398-243.
4
Drug development and obstetrics: where are we right now?
J Matern Fetal Neonatal Med. 2009;22 Suppl 2:46-9. doi: 10.1080/14767050902860377.
5
Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
J Pharm Sci. 2015 Mar;104(3):803-12.
6
Back to the future: driving innovation in drug development.
Clin Pharmacol Ther. 2008 Feb;83(2):199-202. doi: 10.1038/sj.clpt.6100477.
7
Will pharmacogenomics alter the role of patents in drug development?
Pharmacogenomics. 2002 Sep;3(5):571-4. doi: 10.1517/14622416.3.5.571.
8
The optimum time for drug licensing.
Nat Rev Drug Discov. 2003 Sep;2(9):691-2. doi: 10.1038/nrd1181.
9
Pharmacogenetics and drug metabolism.
Nat Biotechnol. 1997 Oct;15(10):925-6. doi: 10.1038/nbt1097-925.
10
The state of innovation in drug development.
Clin Pharmacol Ther. 2008 Feb;83(2):227-30. doi: 10.1038/sj.clpt.6100479.
Zotero 插件